Drug Trial Radar · NCT05535959
A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor
Last checked: Nov 19, 2026Latest source record: Dec 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Sep 15, 2022
Primary completion
Nov 9, 2022
Study completion Nov 9, 2022
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Sep 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the relative bioavailability of a fixed-dose combination tablet (FDC) of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA).
Conditions
- Cystic Fibrosis
Interventions
VX-121/TEZ/D-IVADrug
FDC tablet for oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Plasma Concentration (Cmax) of VX-121, TEZ, and D-IVATime frame: Pre-dose up to 288 hours Post-dose
- Area Under the Concentration Versus Time Curve (AUC) of VX-121, TEZ, and D-IVATime frame: Pre-dose up to 288 hours Post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ICON Salt Lake City
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.